Clinical trial · no report yet · Phase 3
NCT05838066
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
- NCT05838066 ↗
- Recruiting
- Shanghai JMT-Bio Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Open-label, Multicenter, Phase Ш Clinical Study of the Efficacy and Safety of KN026 in Combination With HB1801 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- Interventions
- Recombinant Humanized Bispecific antibody against HER2，KN026; HB1801; Pertuzumab; Trastuzumab; Docetaxel
- Arms
- KN026+HB1801 · Experimental
- Trastuzumab + Pertuzumab + Docetaxel · Active comparator
- Enrollment
- 880 (estimated)
- Primary outcomes
- Free-progression survival (PFS) as evaluated by BIRC (RECIST1.1).
- Sponsor
- Shanghai JMT-Bio Inc.
- Start
- Jul 23, 2023
- Primary completion
- Jul 31, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT05838066 · updated May 30, 2025